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BH4-responsive hyperphenylalaninaemia (HPA) is a
recently described variant of phenylalanine hydroxy-
lase (PAH) deficiency caused by specific mutations in
the PAH gene. Diagnosis is performed by the tetrahy-
drobiopterin (BH4) loading test (20 mg/kg body weight)
and the overall prevalence of BH4-responsiveness within
patients with phenylketonuria (PKU) for blood phenyl-
alanine reduction of 20%, 30%, 40% and 50% was
found to be 48%, 38%, 31% and 24%, respectively, 8 h
after the administration, and 55%, 46%, 41% and
33%, respectively, 24 h after the administration. Using
the standard 30% cut-off, BH4-responsiveness was sim-
ilar regardless of the two modalities in patients with
mild hyperphenylalaninaemia (79–83% responders),
mild PKU (49–60% responders), and classical PKU
(7–10% responders). About 46% of all HPA patients
were responders 24 h post loading (Fiege and Blau
2007). BH4 (drug name Kuvan or Sapropterin) is
registered in the USA (FDA) and is currently under
preregistration in Europe (EMEA) (Burnett 2007).
A number of publications have documented that a
24-hour protocol with 20 mg/kg BH4 is the most com-
monly used method and that multiple administrations
of BH4 and extension of the test to up to one week
may detect some additional Fslow_ responders. How-
ever, some authors use lower doses of BH4 (10 mg/kg)
or a combination of phenylalanine (100 mg/kg) and
BH4 (20 mg/kg), and some authors monitor blood
phenylalanine levels after repeated administration of
BH4 over a period of up to two weeks. In addition,
some of the loading test experiments are performed
under dietary supplementation with a low-phenylalanine
food. This may result in a relative high number of
initially positive responders (>50%) who did not
respond to a long-term treatment, as documented by a
recent multicentre study (Levy et al 2007).
In this issue of the Journal (pp. 67–72), U. Langenbeck
proposes another approach for the classification of
BH4-responsiveness. He calculated the half-life (t1/2) of
blood phenylalanine at different time points following
BH4 administration. Using a log-linear regression, he
compared data from several published reports with the
model of a single exponential decay (SED) of blood
phenylalanine. The conclusion is that only during the
first 15 h after BH4 administration does the kinetic
behaviour of plasma phenylalanine obey first-order
kinetics and that, with a test duration of 24 h, com-
patibility with the SED model is only partial. Indeed,
Fiege and Blau (2007) observed that 2.7% of patients
in whom the loading test was performed over 24 h were
defined as responders only at 8 h. Also, 8.8% of patients
were responders at 24 h, but not at 8 h. In about 15% of
all patients who responded to BH4 by 20%, blood
phenylalanine levels increased from 8 h to 24 h by at
least 10%. Accordingly, they suggest that the BH4
loading test should be modified to include a second
administration of 10–20 mg/kg BH4 at time 12 h and
assessment of plasma phenylalanine levels at times 0, 8,
12 and 24 h after BH4 administrations. Thus, additional
investigations are necessary in order to evaluate the
importance of the 12– or 15-hour blood phenylalanine
values. Long-term (1–2 weeks) loading tests are more
expensive and definitely not practical for the initial
screening.
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Langenbeck further suggests in his article that
genotype–phenotype analysis may benefit from the
t1/2-driven diagnostic approach and that knowledge of
individual t1/2 values and age-specific protein synthesis
could improve therapeutic decisions. Data from the
BIOPKU database demonstrate that the genotype-
predicted BH4-responsiveness is on average higher
than that obtained from the BH4 loading test and that
the patient_s genotype may certainly exclude non-
responsiveness and to some extent predict a potential
responder (Zurflu¨h et al 2008). A combination of the
BH4 loading test and genotype analysis together with
the phenylalanine kinetics (t1/2) may certainly improve
the definition of the BH4-responsiveness.
On the basis of present knowledge, guidelines for
the definition of BH4-responsiveness should include
the following investigations: (1) Single loading test
with BH4 (20 mg/kg) and monitoring of blood phenyl-
alanine at 0, 8, 12 (15), and 24 h. (2) Reduction of
blood phenylalanine levels of >20–30% as an indicator
for a trial with BH4 (initial doses of 10 mg/kg) over
several weeks. (3) Titration of the individual BH4
requirement (5–20 mg/kg) to maintain optimal blood
phenylalanine levels. (4) Determination of the daily
phenylalanine tolerance. (5) Genotyping.
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